Metal-phenolic nanozyme as a ferroptosis inhibitor for alleviating cisplatin-induced acute kidney injury
Frontiers in Pharmacology · 01.04.2025 · 16
DOI: 10.3389/fphar.2025.1535969 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 01.04.2025. Verfasst von Yunfeng Xiong und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Fujian Medical University Union Hospital, Fuzhou, China. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Cisplatin-induced acute kidney injury (AKI) is primarily caused by oxidative stress from reactive oxygen species (ROS) accumulation. Developing ROS scavengers presents promising opportunities for preventing and treating this condition by targeting oxidative stress mechanisms.
Methods
This study involves the fabrication of a metal-polyphenol self-assembled nanozyme (Fe@Ba) designed to inhibit ferroptosis through synergistic catalytic actions and antioxidant properties. The nanozyme is constructed using metal-polyphenol coordination-driven nanoprecipitation techniques. Its performance is evaluated in vitro using MTEC cells and in vivo within an AKI model, with assessments of catalytic activities, ROS depletion efficacy, antioxidant effects, and anti-ferroptotic mechanisms.
Results
The Fe@Ba nanozyme demonstrates significant catalase (CAT) and superoxide dismutase (SOD)-like activities upon internalization by MTEC cells, effectively reducing high ROS levels in the AKI model. Baicalein (Ba), a traditional Chinese medicine component in the nanozyme, exhibits strong antioxidant properties, inhibits lipid peroxidation (LPO), upregulates reductive glutathione (GSH), and promotes glutathione peroxidase 4 (GPX4) expression, thereby inhibiting ferroptosis. Fluorescence imaging confirms effective renal accumulation of Cy5.5-labeled Fe@Ba nanozyme. In vivo experiments show the nanozyme reduces inflammation and significantly enhances survival rates in AKI models.
Discussion
This study validates the concept of self-assembling nanozymes for AKI treatment and offers new insights into nanomedicine applications. The Fe@Ba nanozyme's ability to counteract inflammation-related damage and inhibit ferroptosis through multiple mechanisms highlights its therapeutic potential. The successful integration of traditional Chinese medicine components with nanotechnology represents an innovative approach to addressing cisplatin-induced AKI, suggesting broader applications for metal-polyphenol nanozymes in oxidative stress-related kidney diseases.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Nephrology, Fujian Medical University Union Hospital, Fuzhou, China.
- Department of Pediatrics, Fujian Medical University Union Hospital, Fuzhou, China.
- CAS Key Laboratory of Soft Matter Chemistry, Department of Chemistry, University of Science and Technology of China, Hefei, China.
- Fujian Institute of Clinical Immunology, Fuzhou, China.
Zitieren
APA
Xiong, Y., Kang, H., Rao, Y., Huang, X., Zhu, Y., & Wei, L. (2025). Metal-phenolic nanozyme as a ferroptosis inhibitor for alleviating cisplatin-induced acute kidney injury. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1535969
Vancouver
Xiong Y, Kang H, Rao Y, Huang X, Zhu Y, Wei L. Metal-phenolic nanozyme as a ferroptosis inhibitor for alleviating cisplatin-induced acute kidney injury. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1535969
BibTeX
@article{Xiong2025,
author = {Xiong, Yunfeng and Kang, Huimin and Rao, Yanping and Huang, Xiayu and Zhu, Yang and Wei, Lixin},
title = {Metal-phenolic nanozyme as a ferroptosis inhibitor for alleviating cisplatin-induced acute kidney injury},
journal = {Frontiers in Pharmacology},
year = {2025},
volume = {16},
doi = {10.3389/fphar.2025.1535969}
}
EUVIMED